Celerion Expands Clinical Research to Nebraska Innovation Campus

Nebraska Innovation Campus has announced a new partner. Dan Duncan, NIC’s executive director, said Celerionwillmove into this space on the campus in February of 2020.

Celerion has been conducting clinical research studies over 50 years in Lincoln Nebraska for pharmaceutical and biotechnology companies around the world, for investigational medicines currently in research and development, to treat a wide variety of illnesses and conditions.

Celerionwill be located on the first level ofthe Rise Building, NIC’s newest building. An open house will be hosted at the Rise Building in March. This event will provide Celerion staff the opportunity to learn about ways to partner with faculty and students, and for visitors to learn more about pharmaceutical research opportunities atCelerionand the drug development process.

“Celerion is a great long-term fit for NIC,” Duncan said. “Their clinical research expertise will be invaluable as theNebraskaFood for Health Center continues to develop and companies in the Biotech Connector mature.”

“Celerion is pleased to announce NIC as the location for our expansion,” commented Phil Bach, Vice President, Global Clinical Research, Celerion.“We’re excited to take this next step to further our client’s goals for drug development. This space will allow us to partner with top notch students, faculty and entrepreneurs at NIC and collaborate at the forefront of the biotechnology hub in Nebraska.

”The new location atNIC demonstrates Celerion’s commitment to innovation and excellence in clinical research, Bach said.

“We are committed to scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path,” Bach noted. “Establishing a partnership at NIC will allow us to provide new service avenues as clients look to bring their drugs to the market”.

NIC is a campus designed to facilitate new and in-depth partnerships between the university and private sector businesses. At full build-out, NIC will be a 2.2-million square-foot campus with uniquely designed buildings and amenities that inspire creative activity and engagement, transforming ideas into global innovation. For more information, visit http://www.innovate.unl.edu.

Tetrad Property Group is the private sector development partner for NIC. Tetrad provides a full range of development services for the campus, including master planning, construction management, leasing and property management. For more information, visit http://www.tetradpropertygroup.com.

Celerion, a global leader in early clinical research services offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. For fifty years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic and pharmacodynamics studies in highly controlled clinic environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. Celerion offers feasibility, data management, biostatistics, clinical monitoring, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends and people in need around the world. For more information, please visitwww.celerion.com.